DBV Technologies (DBVTF) reported a net loss of $64.5 million, or $0.14 per basic and diluted share, for the third quarter ended September 30, 2026. Research and development expense was $47.0 million, sales and marketing expense was $5.3 million, and general and administrative expense was $14.0 million.
The company submitted a Biologics License Application to the U.S. FDA for its VIASKIN Peanut Patch in children ages 4 through 7 and requested Priority Review. DBV reported $165.7 million in cash and cash equivalents at September 30, 2026.
- Net loss increased from $33.2 million in the third quarter of 2025.
- Operating income was $1.6 million, compared with $2.8 million a year earlier.
- DBV completed a $50.0 million gross-proceeds sale of ADSs under its ATM program during the quarter.
- The company estimates existing cash will fund operations into the third quarter of 2027.
- Management said substantial doubt exists about its ability to continue as a going concern within 12 months of the financial statements' issuance.
EARLY ACCESS
Receive DBVTF Data Alerts
Real-time alerts on filings, insider trades, and market signals — before everyone else.
Get Alerts →
